- Home
- COE vs ENTX Comparison
COE vs ENTX Comparison
Compare COE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- ENTX
- Stock Information
- Founded
- COE 2011
- ENTX 2010
- Country
- COE Singapore
- ENTX Israel
- Employees
- COE N/A
- ENTX N/A
- Industry
- COE Other Consumer Services
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COE Real Estate
- ENTX Health Care
- Exchange
- COE Nasdaq
- ENTX Nasdaq
- Market Cap
- COE 76.7M
- ENTX 67.2M
- IPO Year
- COE 2016
- ENTX 2018
- Fundamental
- Price
- COE $15.45
- ENTX $2.25
- Analyst Decision
- COE
- ENTX Strong Buy
- Analyst Count
- COE 0
- ENTX 1
- Target Price
- COE N/A
- ENTX $10.00
- AVG Volume (30 Days)
- COE 10.3K
- ENTX 54.3K
- Earning Date
- COE 12-13-2024
- ENTX 11-08-2024
- Dividend Yield
- COE N/A
- ENTX N/A
- EPS Growth
- COE N/A
- ENTX N/A
- EPS
- COE N/A
- ENTX N/A
- Revenue
- COE $41,924,000.00
- ENTX $99,000.00
- Revenue This Year
- COE N/A
- ENTX N/A
- Revenue Next Year
- COE N/A
- ENTX N/A
- P/E Ratio
- COE N/A
- ENTX N/A
- Revenue Growth
- COE 69.79
- ENTX 607.14
- 52 Week Low
- COE $6.00
- ENTX $0.52
- 52 Week High
- COE $19.75
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- COE 58.99
- ENTX 68.35
- Support Level
- COE $15.26
- ENTX $2.02
- Resistance Level
- COE $17.96
- ENTX $2.28
- Average True Range (ATR)
- COE 1.09
- ENTX 0.17
- MACD
- COE 0.33
- ENTX 0.04
- Stochastic Oscillator
- COE 68.88
- ENTX 77.01
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.